

## REMARKS

This Response is submitted in response to the Office Action mailed on February 8, 2006. This Response is filed within one month of the Office Action mail date and is, therefore, timely filed.

The Office Action is a Restriction Requirement. In this regard, Applicants are required to restrict the application to one of six alleged groups of invention. According to the Office Action, the following inventions are distinct from each other:

Group I (Claims 1-13) drawn to a method of selecting a neurogenic agent;

Group II (Claim 14) drawn to a method of treating a disorder by administering an imidazole;

Group III (Claim 15) drawn to a method of treating a disorder by administering an aminopyrimidine;

Group IV (Claim 16) drawn to method of treating a disorder by administering a nicotinamide;

Group V (Claim 17) a method of treating a disorder by administering an aminomethyl phenoxypiperidine; and

Group VI (Claim 18) drawn to a method for treating a disorder by administering an aryloxypiperidine.

Applicants have added new Claims 19 and 20. Applicants respectfully submit that new Claims 19 and 20 are genus claims linking the species of Groups II, III, IV, V and VI. In view thereof, Applicants elect, with traverse, Group II (Claim 14) and note that at least new Claims 19 and 20 are readable thereon. In the event Claims 19 and 20 are allowed, Applicants further submit that Applicants are entitled to retain claims directed to non-elected Groups III, IV, V and VI in accordance with MPEP §809.

Additionally, Applicants reserve the right to file one or more divisional applications to the non-elected claims.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY 

Bradley E. Davis

Reg. No. 56,727

Customer No. 24573

Dated: March 7, 2006